Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2019 According to an Akcea Therapeutics media release, data from the NEURO-TTR open-label study will be presented at the 2nd European ATTR Amyloidosis Alliance Meeting in Berlin, Germany, September 2-3, 2019.
    • 26 Jun 2019 According to an Akcea Therapeutics media release, long-term efficacy and safety data from this trial will be presented at the 5th European Academy of Neurology Annual Congress (EAN) 2019.
    • 07 May 2019 According to an Akcea Therapeutics media release, long term data from the open-label extension of this study were presented at the 2019 American Academy of Neurology (AAN) Annual Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top